GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

RFRP-3   Click here for help

GtoPdb Ligand ID: 4016

Synonyms: neuropeptide RFRP-3 | NPVF
Compound class: Endogenous peptide in human, mouse or rat
Species: Human
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Gouardères C, Mazarguil H, Mollereau C, Chartrel N, Leprince J, Vaudry H, Zajac JM. (2007)
Functional differences between NPFF1 and NPFF2 receptor coupling: high intrinsic activities of RFamide-related peptides on stimulation of [35S]GTPgammaS binding.
Neuropharmacology, 52 (2): 376-86. [PMID:17011599]
2. Gouardères C, Quelven I, Mollereau C, Mazarguil H, Rice SQ, Zajac JM. (2002)
Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands.
Neuroscience, 115 (2): 349-61. [PMID:12421602]
3. Gouardères C, Zajac JM. (2007)
Biochemical anti-opioid action of NPFF2 receptors in rat spinal cord.
Neurosci Res, 58 (1): 91-4. [PMID:17337079]
4. Mollereau C, Mazarguil H, Marcus D, Quelven I, Kotani M, Lannoy V, Dumont Y, Quirion R, Detheux M, Parmentier M et al.. (2002)
Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists.
Eur J Pharmacol, 451 (3): 245-56. [PMID:12242085]